Conshohocken-based AmerisourceBergen Corp., a global healthcare company, recently signed an agreement to purchase Germany-based PharmaLex Holding GmbH for $1.28 billion in cash.
PharmaLex provides strategic guidance and regulatory support services to the life sciences industry throughout a product’s lifecycle, including clinical development consulting and marketing authorization. It has a large presence in Europe and the United States, with a growing presence worldwide.
By purchasing PharmaLex, AmerisourceBergen will enhance its portfolio of solutions, expand its existing European presence in pharmaceutical distribution and biopharma manufacturer services capabilities, advance several strategic imperatives, and take advantage of growth opportunities in the biopharma market.
“AmerisourceBergen is committed to building on our leadership in specialty services through a continued focus on innovation and partnerships, and by acquiring PharmaLex, we will be able to further enhance our value proposition to pharmaceutical manufacturers, from emerging biotechs to global biopharmaceutical leaders,” Steven Collis, AmerisourceBergen chairman, president and CEO, said.
The deal is expected to close by March and is subject to customary closing conditions and required regulatory approvals. Once completed, PharmaLex will become a component within AmerisourceBergen’s International Healthcare Solutions segment.
AmerisourceBergen employs 42,000 people worldwide and generates more than $200 billion in annual revenue.